| 1. |
- Engert, Andreas, et al.
(author)
-
The European Hematology Association Roadmap for European Hematology Research : a consensus document
- 2016
-
In: Haematologica. - Pavia, Italy : Ferrata Storti Foundation (Haematologica). - 0390-6078 .- 1592-8721. ; 101:2, s. 115-208
-
Journal article (peer-reviewed)abstract
- The European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better funded, more focused European hematology research. Initiated by the EHA, around 300 experts contributed to the consensus document, which will help European policy makers, research funders, research organizations, researchers, and patient groups make better informed decisions on hematology research. It also aims to raise public awareness of the burden of blood disorders on European society, which purely in economic terms is estimated at (sic)23 billion per year, a level of cost that is not matched in current European hematology research funding. In recent decades, hematology research has improved our fundamental understanding of the biology of blood disorders, and has improved diagnostics and treatments, sometimes in revolutionary ways. This progress highlights the potential of focused basic research programs such as this EHA Roadmap. The EHA Roadmap identifies nine 'sections' in hematology: normal hematopoiesis, malignant lymphoid and myeloid diseases, anemias and related diseases, platelet disorders, blood coagulation and hemostatic disorders, transfusion medicine, infections in hematology, and hematopoietic stem cell transplantation. These sections span 60 smaller groups of diseases or disorders. The EHA Roadmap identifies priorities and needs across the field of hematology, including those to develop targeted therapies based on genomic profiling and chemical biology, to eradicate minimal residual malignant disease, and to develop cellular immunotherapies, combination treatments, gene therapies, hematopoietic stem cell treatments, and treatments that are better tolerated by elderly patients.
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Dreyling, Martin, et al.
(author)
-
Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma Network
- 2015
-
In: Leukemia & Lymphoma. - : Informa UK Limited. - 1042-8194 .- 1029-2403. ; 56:4, s. 866-876
-
Research review (peer-reviewed)abstract
- Mantle cell lymphoma (MCL) is a distinct subtype of malignant lymphoma which is characterized by the chromosomal translocation t(11;14)(q13;q32) resulting in constitutional overexpression of cyclin D1 and cell cycle dysregulation in almost all cases. Clinically, MCL shows an aggressive clinical course with a continuous relapse pattern and a median survival of only 3-5 years. However, recently a subset of 15% long-term survivors has been identified with a rather indolent clinical course. Targeted strategies include the proteasome inhibitors, immune modulatory drugs (IMiDs), mammalian target of rapamycin (mTOR) inhibitors and especially inhibitors of the B-cell receptor pathway. Our recent annual conference focused on the molecular pathogenesis of the disease and how these underlying molecular alterations may guide the selection and integration of innovative approaches for therapy. This review of the meeting covers in particular the identification of indolent cases, and deals with the role of the B-cell receptor pathway in MCL, as well as the detection of minimal residual disease and implementation of molecular approaches in current clinical trials.
|
|
| 5. |
- Hess, Georg, et al.
(author)
-
Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus
- 2017
-
In: Leukemia and Lymphoma. - : Informa UK Limited. - 1042-8194 .- 1029-2403. ; 58:12, s. 2824-2832
-
Journal article (peer-reviewed)abstract
- Mantle cell lymphoma (MCL) is a rare, aggressive, incurable B-cell malignancy. Ibrutinib has been shown to be highly active for patients with relapsed/refractory (R/R) MCL. The RAY trial (MCL3001) was a phase 3, randomized, open-label, multicenter study that compared ibrutinib with temsirolimus in patients with R/R MCL. Active disease is frequently associated with impaired functional status and reduced well-being. Therefore, the current study employed two patient-reported outcome instruments, the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) and the EQ-5D-5L, to assess symptoms, well-being, health status, and health-related quality of life of patients on treatment within the RAY trial. We found that patients on ibrutinib had substantial improvement in FACT-Lym subscale and total scores, and had improvement in EQ-5D-5L utility and VAS scores compared with temsirolimus patients, indicating a superior well-being. These improvements in well-being correlated with clinical response, indicating that better health-related quality of life was associated with decreased disease burden.
|
|
| 6. |
- Katrantsiotis, Christos, et al.
(author)
-
Late quaternary hydroclimate variability in Madagascar and its connection to atmospheric circulation patterns
- 2024
-
In: Palaeogeography, Palaeoclimatology, Palaeoecology. - : Elsevier. - 0031-0182 .- 1872-616X. ; 649
-
Journal article (peer-reviewed)abstract
- Large uncertainties still exist about the long-term mechanisms influencing the hydroclimate variability of southeast Africa where proxy data and model simulations indicate rainfall dipoles between subtropical and tropical areas. The topography of Madagascar, located off the southeastern coast of Africa, modulates these dipoles while its climate is influenced by the position of the Intertropical Convergence Zone (ITCZ) and the Subtropical High as well as the sea surface temperature (SST) of SW Indian Ocean. The island can thus be considered a key location for the understanding of the tropical SE African climatic variability and the interplay between atmospheric patterns. However, the scarcity of continuous records from Madagascar has made the evolution of regional late Quaternary climate and its driving mechanisms difficult to assess. Here, we present a 26-kyr record of the deuterium/hydrogen isotope ratio (δD) of biomarkers (n-alkanes) from the central eastern part of the island at Antananarivo at around 1250 m a.s.l. Preliminary summary pollen data are also presented as a comparison. The δD profiles of aquatic plant and terrestrial plant-derived n-alkanes generally exhibit similar trends implying that they all record changes in the isotope composition of source water, namely meteoric water that recharges soil and lake waters. In this tropical region, the δD variability of precipitation is mainly influenced by the amount effect reflecting the intensity of precipitation associated with the monsoon. We observe: (i) stable and wet conditions during the Last Glacial Maximum, (ii) drier conditions from 18.5 to 15 ka (ka before present) during the Heinrich Stadial 1 (iii) high humidity after 15 ka culminating at the Younger Dryas (YD), (iv) drier conditions from 11.7 ka to 8.2 ka, (v) a return to humid climate until 2.8 ka, and (vi) an arid phase followed by increased wetness after 0.9 ka, although the record is likely influenced by human-induced vegetation changes the last 1.2 ka. This climate signal is similar to other records from the Mozambique Channel but opposite to records from the East African mainland and the subtropical southern Africa, especially between 20 and 25°S. Although there is a good correspondence of our record with insolation- driven migrations of ITCZ during the LGM and the early Holocene, the dipoles are largely consistent with the modern rainfall anomaly and are best explained by the interlinked effects of the SST changes and the variability of the Mozambique Channel Trough.
|
|
